Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00360425 · ClinicalTrials.gov registry record · Phase 1
A Study of the Electrocardiogram Effects and Pharmacokinetics of Ferumoxytol in Healthy Men and Women
A Phase 1 study of Anemia, sponsored by AMAG Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 174
- Enrollment target
- 1
- Study location
NCT00360425: Completed Phase 1 study of Anemia, sponsored by AMAG Pharmaceuticals.
NCT00360425 is a Phase 1 study of Anemia that has completed, run by AMAG Pharmaceuticals. The registered enrollment target is 174 participants, below the 425-participant average among 72 other Anemia trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00360425, a Phase 1 study of Anemia, has completed, sponsored by AMAG Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 174 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will define the effects of ferumoxytol on electrocardiogram (ECG) data as well as evaluate pharmacokinetics
Conditions Studied
Interventions
- DRUG placebo
- DRUG ferumoxytol
- DRUG moxifloxacin
Study Locations (1)
Maryland
- - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2006-05 |
| Est. Completion | 2006-08 |
| Phase | Phase 1 |
What the finished NCT00360425 record still lists
NCT00360425 is an interventional study that assigns participants to a tested intervention. The registered 174 participants enrollment target is mid-sized for trials with a published cap, below the 425-participant average among 72 other Anemia trials with a reported enrollment target (59% lower).
The record links to 1 condition, with Anemia appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT00360425 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00360425 about?
NCT00360425 is a clinical study titled "A Study of the Electrocardiogram Effects and Pharmacokinetics of Ferumoxytol in Healthy Men and Women". This study will define the effects of ferumoxytol on electrocardiogram (ECG) data as well as evaluate pharmacokinetics
What is the current status of trial NCT00360425?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 174 participants. The study started on 2006-05. Estimated completion is 2006-08.
What conditions does trial NCT00360425 study?
This clinical trial studies the following conditions: Anemia.
What interventions are being tested in trial NCT00360425?
The interventions under investigation include: placebo (DRUG), ferumoxytol (DRUG), moxifloxacin (DRUG).
Who is sponsoring clinical trial NCT00360425?
This trial is sponsored by AMAG Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00360425 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00360425's enrollment target sits among peer trials
174 36th of 72 higher than 37 of 72 other Anemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
-
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 1 Study of LY2787106 in Cancer and Anemia
COMPLETED · Phase 1
-
BioRBC Survival in Adults With Prior Antibody Response to BioRBCs
COMPLETED · Phase 1
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
Study of DISC-0974-201 in Participants With IBD and Anemia
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01000259 · 174 participants
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
- NCT04729114 · 174 participants · Phase 1
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
- NCT04884035 · 174 participants · Phase 1
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
- NCT05075980 · 174 participants · Phase 2
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia